What each step is for
The chart has six rows, but they don’t all mean the same thing. Some are places to stay; others are stops on the way up (Zepbound and Mounjaro prescribing information):
- 2.5 mg: where everyone starts, for at least four weeks, so the body can get used to the medicine. For Zepbound it’s never a dose to stay on. For Mounjaro, since August 2026, it can also be an ongoing dose for blood-sugar control.
- 5 mg: the first possible maintenance dose for weight on Zepbound.
- 7.5 mg: a step on the way to 10 mg.
- 10 mg: a maintenance dose for weight or sleep apnea on Zepbound, and the highest Mounjaro dose for children 10 and older.
- 12.5 mg: a step on the way to 15 mg.
- 15 mg: the maximum. A maintenance dose for weight or sleep apnea on Zepbound.
You don’t have to reach 15 mg. The Zepbound label asks prescribers to pick the maintenance dose based on how you respond and what you tolerate, and 5 and 10 mg are maintenance doses in their own right.
When a dose is hard to tolerate
Digestive side effects are the main reason the steps are slow, and they tend to rise with the dose. In the Zepbound weight-reduction trials, nausea affected 25%, 29% and 28% of people on 5, 10 and 15 mg, against 8% on placebo (Zepbound prescribing information). The days after a step-up are usually the hardest.
The labels give your prescriber two levers. Each increase comes after at least four weeks, so staying longer on a dose before moving up is within the label. And if a maintenance dose isn’t tolerated, the Zepbound label says a lower maintenance dose can be considered.
In practice, a multidisciplinary expert consensus on digestive side effects of this class of medicines describes the usual order of steps (Gorgojo-Martínez et al., J Clin Med 2022):
- Change how you eat first: smaller meals, stopping as soon as you feel full, less fatty, fried or spicy food, and fluids sipped between meals rather than with them.
- Hold the dose: stay on the current step for longer instead of moving up on schedule.
- Step back: if symptoms started after an increase, return to the previous dose for a while, then go up more slowly.
- Settle lower: a maintenance dose below the maximum is a fine place to stay.
The SURMOUNT-1 trial worked the same way. Participants with digestive symptoms got eating advice first and could take anti-nausea or anti-diarrhea medicine. If that wasn’t enough, they could skip one dose, and then move down once to the next maintenance dose (15 to 10 mg, or 10 to 5 mg). Those who still couldn’t tolerate it stopped (SURMOUNT-1 protocol). Each of these steps is your prescriber’s call; the list is there so you know what to ask about.
Call your prescriber promptly if you have severe stomach pain that doesn’t go away, sometimes reaching through to the back (the label lists it as a possible sign of pancreatitis); vomiting or diarrhea that keeps you from holding down fluids, since dehydration can harm the kidneys; or pain in the upper right belly, fever or yellowing skin, which can point to the gallbladder (Zepbound prescribing information). Our tirzepatide side effects guide covers the rest.
What each maintenance dose did in the trial
In SURMOUNT-1, adults with obesity and without diabetes were assigned one maintenance dose and stayed on it (Jastreboff et al., NEJM 2022):
| Maintenance dose | Average weight lost after 72 weeks |
|---|---|
| 5 mg | 15.0% |
| 10 mg | 19.5% |
| 15 mg | 20.9% |
| Placebo | 3.1% |
These are averages across thousands of people, alongside diet and exercise advice. Individual results vary a lot, in both directions.
Missed doses, late doses and changing your day
| Situation | What the label says |
|---|---|
| 4 days (96 hours) or less since the missed day | Take it as soon as possible |
| More than 4 days | Skip it; take the next dose on your usual day |
| Moving your shot day | Allowed if the two doses are at least 3 days (72 hours) apart |
| Missed several weeks in a row | No rule in the labels; ask your prescriber which dose to restart on before your next shot |
The first three rows come from both labels. For longer breaks, the closest thing to an answer is what the SURMOUNT trials did, as Eli Lilly’s medical information team describes it: after one or two missed doses in a row, people restarted at the same dose if they’d tolerated it before; after three or more, they restarted at 5 mg, whatever dose they’d been on, and stepped up again from there (Lilly Medical, reviewed January 2026). That’s trial practice, not a dosing instruction, but it shows why going straight back to 15 mg after a month off is something to talk through first: side effects are dose-related, and the body has lost its tolerance.
Pens, KwikPens and vials
All four devices hold the same medicine, and every dose on the chart is in milligrams whichever you use.
| Device | Weekly doses inside | Out of the refrigerator |
|---|---|---|
| Single-dose pen | 1 | Up to 30 °C (86 °F) for a total of 21 days |
| Single-dose vial | 1 | Up to 30 °C (86 °F) for a total of 21 days |
| KwikPen | 4 | Discard 30 days after first use or after 4 doses |
| Multi-dose vial | 4 | Discard 30 days after first use or after 4 doses |
Before use, all of them are kept in the refrigerator (2–8 °C / 36–46 °F). Single-dose pens and vials come in all six strengths. Inject under the skin of the abdomen or thigh, or the back of the upper arm if someone else gives the shot, and rotate the site each week (Zepbound prescribing information).
One medicine, two labels
Mounjaro and Zepbound are both tirzepatide from Eli Lilly, in the same strengths and with the same four-week steps. Where they differ is what each dose is for: Zepbound names maintenance doses for weight and sleep apnea and treats 2.5 mg as a starting dose only; Mounjaro, for type 2 diabetes, allows 2.5 mg as an ongoing dose and caps children at 10 mg. Each brand has its own page: the Mounjaro dosage chart and the Zepbound dosage chart. Outside the US, Mounjaro is also authorised for weight management in the UK and EU, with the same steps.
Before surgery, during pregnancy, and with the pill
- Surgery or sedation: tell the team doing any planned surgery or procedure that you take tirzepatide. The label warns about the risk of breathing in stomach contents under general anesthesia or deep sedation.
- Pregnancy: the Zepbound label says to stop when a pregnancy is recognized. Talk to your prescriber if you’re planning one.
- Birth control pills: tirzepatide can make them less effective. Both labels advise switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each dose increase. That’s one more reason to keep the dates of your steps.
Questions the labels leave open, and what we found
Some of the most searched questions about tirzepatide dosing have no answer in the prescribing information. Here’s what the manufacturer’s medical team and the trials say instead, and where the honest answer is “no one knows”:
- Switching from semaglutide (Ozempic or Wegovy): there’s no official method and no dose equivalence. Lilly says plainly that it can’t recommend how to switch from another GLP-1 medicine to tirzepatide or give a conversion between them (Lilly Medical). In two switching trials in type 2 diabetes, there was no gap between the medicines: one started tirzepatide at 2.5 mg within three days of the next scheduled dose of the old one; the other started at 5 mg, three to ten days after the last weekly dose. Any “semaglutide to tirzepatide conversion chart” you find online isn’t based on either label.
- Restarting after weeks off: see the table above. The labels are silent; the trials restarted at 5 mg after three or more missed doses.
- Microdosing or splitting a dose: Lilly doesn’t recommend it. It hasn’t studied splitting a KwikPen or multi-dose vial into smaller doses, the instructions don’t cover giving less than the full dose, and splitting a single-dose pen or vial may raise the risk of contamination (Lilly Medical, reviewed August 2026). If the lowest maintenance dose is too much, that’s a conversation for your prescriber, not a pen to divide.
- Syringe units for compounded tirzepatide: see the next section.
Compounded tirzepatide and syringe units
Many people searching for a tirzepatide dosage chart use tirzepatide from a compounding pharmacy, drawn from a vial with a syringe marked in units. How many units make a given number of milligrams depends on the concentration of that vial, and concentrations differ between pharmacies. A units chart from one pharmacy can be wrong, by a lot, for a vial from another. That’s why this chart lists milligrams only: the units for your dose come from your own pharmacy’s label and your prescriber.
The risk isn’t theoretical. With compounded semaglutide, sold the same way, the FDA received reports of people injecting five to 20 times the intended dose after mixing up milliliters, milligrams and units, some of whom were hospitalized (FDA, July 2024). If the numbers on your vial, syringe and instructions don’t line up, ask your pharmacist before you inject.
The FDA states that compounded drugs are not FDA-approved, meaning the agency doesn’t review them for safety, effectiveness or quality before they’re sold (FDA). The FDA declared the tirzepatide injection shortage, which had allowed wider compounding, resolved in December 2024 (FDA).
Keeping a record of each step
Six possible doses, a birth-control window after each increase, and a four-day missed-dose cutoff add up to a lot of dates. Mingo saves the dose with every shot and colors the weight chart by dose, so after a few months you can see which step brought the most change and which brought side effects. It also draws an estimated medication level from your logged doses and tirzepatide’s half-life of about five days, which helps make sense of how you feel across the week. Mingo accepts any dose in milligrams, including compounded tirzepatide, but it doesn’t convert syringe units; that math belongs to your pharmacist and prescriber.


